Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Eric Jahnke

Gastroenterology Santa Maria, CA Medical Doctor

NPI 1134195977 CMS profile 96432

361 Town Center West Suite 101, Santa Maria, CA 93458

Open in the dashboard

General payments

$4,027

221 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Eric Jahnke of Santa Maria, CA is reported in the CMS Open Payments database as having received $4,027 across 221 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $90 3
2023 General $167 4
2022 General $1,861 103
2021 General $1,210 80
2020 General $260 11
2019 General $440 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Jahnke
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Eric Jahnke were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Eric Jahnke Gastroenterology median Middle half National median
2019 $440 $417 $126–$1,100 $163
2020 $260 $224 $74–$624 $114
2021 $1,210 $352 $106–$1,054 $132
2022 $1,861 $448 $129–$1,270 $149
2023 $167 $533 $150–$1,390 $160
2024 $90 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AbbVie, Inc. $2,302 139 payments
  2. Janssen Biotech, Inc. $474 25 payments
  3. Gilead Sciences, Inc. $267 5 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $155 9 payments
  5. Nestle HealthCare Nutrition Inc. $141 8 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $139 9 payments
  7. Genzyme Corporation $132 1 payment
  8. Ferring Pharmaceuticals Inc. $95 5 payments
  9. Celgene Corporation $85 6 payments
  10. Pfizer Inc. $77 5 payments
  11. Other $162 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $3,928 220 payments
  2. Education $99 1 payment
Products named General payments · program years 2019–2024
  1. CREON $1,044 67 payments
  2. LINZESS $892 55 payments
  3. HUMIRA $494 34 payments
  4. STELARA $474 25 payments
  5. RINVOQ $315 19 payments
  6. Epclusa $217 2 payments
  7. SKYRIZI $181 7 payments
  8. XIFAXAN $152 9 payments
  9. ZENPEP $141 8 payments
  10. DUPIXENT $132 1 payment
  11. Other $1,059 67 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

221 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record